Recent guidelines recommend that Lp(a) should be measured in every adult at least once in a lifetime to identify those with very high Lp(a) levels, i.e., >180 mg/dL (>450 nmol/L), and these individuals are considered to have similar ASCVD risk as individuals with heterozygous familial hypercholesterolemia (FH) [20,21,22]. Here, LPA is linked to familial hyperaldosteronism.